Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. DNLI
DNLI logo

DNLI

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

DNLI News

US Stocks Close Higher as Market Sentiment Improves

May 22 2026NASDAQ.COM

US Stocks Rise, Nasdaq Hits Weekly High

May 22 2026NASDAQ.COM

US Stocks Rise as Market Optimism Grows

May 22 2026NASDAQ.COM

Biogen and Denali Halt Development of Parkinson's Drug BIIB122

May 22 2026seekingalpha

Biogen and Denali Halt Development of Parkinson's Drug BIIB122

May 22 2026NASDAQ.COM

Biogen and Denali Halt Parkinson's Drug Development

May 21 2026stocktwits

Biogen and Denali Discontinue BIIB122 Development in Parkinson's Disease

May 21 2026Globenewswire

Biogen and Denali Discontinue BIIB122 Development in Parkinson's Disease

May 21 2026Newsfilter

ADAR1 Capital Management Increases Stake in Denali Therapeutics

May 18 2026Fool

Denali Therapeutics Q1 Financial Results Analysis

May 07 2026seekingalpha

Privium Fund Management Acquires Stake in Denali Therapeutics

May 05 2026Fool

Transformation of Value in Biotechnology Sector

Apr 20 2026Globenewswire

Biotechnology Sector Undergoes Value Transformation

Apr 20 2026Newsfilter

Denali Regains Full Rights to DNL593 Therapy

Apr 06 2026NASDAQ.COM

Denali Continues Clinical Development of DNL593 After Takeda Collaboration Termination

Apr 03 2026Newsfilter

Takeda Ends Collaboration Agreement with Denali Therapeutics on DNL593

Apr 03 2026moomoo